171 related articles for article (PubMed ID: 37343168)
21. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
[TBL] [Abstract][Full Text] [Related]
22. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
Balani S; Perwad F
Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
[TBL] [Abstract][Full Text] [Related]
23. Burosumab treatment for fibrous dysplasia.
Gladding A; Szymczuk V; Auble BA; Boyce AM
Bone; 2021 Sep; 150():116004. PubMed ID: 33984553
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review.
Dodamani MH; Kumar SC; Bhattacharjee S; Barnabas R; Kumar S; Ranjan Lila A; Samad Memon S; Karlekar M; A Patil V; R Bandgar T
Arch Endocrinol Metab; 2024 May; 68():e230242. PubMed ID: 38788147
[TBL] [Abstract][Full Text] [Related]
25. Burosumab: Current status and future prospects.
Goyal A; Tandon N
Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101826. PubMed ID: 37858479
[TBL] [Abstract][Full Text] [Related]
26. Burosumab for Pediatric X-Linked Hypophosphatemia.
Imel EA
Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
[TBL] [Abstract][Full Text] [Related]
27. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
28. Rickets guidance: part II-management.
Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
[TBL] [Abstract][Full Text] [Related]
29. Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone.
Ertl DA; Le Lorier J; Gleiss A; Trabado S; Bensignor C; Audrain C; Zhukouskaya V; Coutant R; Berkenou J; Rothenbuhler A; Haeusler G; Linglart A
Orphanet J Rare Dis; 2022 Nov; 17(1):412. PubMed ID: 36371259
[TBL] [Abstract][Full Text] [Related]
30. Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.
Weber TJ; Imel EA; Carpenter TO; Peacock M; Portale AA; Hetzer J; Merritt JL; Insogna K
J Clin Endocrinol Metab; 2022 Dec; 108(1):155-165. PubMed ID: 36072994
[TBL] [Abstract][Full Text] [Related]
31. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries.
Mughal MZ; Baroncelli GI; de Lucas-Collantes C; Linglart A; Magnolato A; Raimann A; Santos F; Schnabel D; Shaw N; Nilsson O
Front Endocrinol (Lausanne); 2022; 13():1034580. PubMed ID: 36798486
[TBL] [Abstract][Full Text] [Related]
32. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.
Harada D; Ueyama K; Oriyama K; Ishiura Y; Kashiwagi H; Yamada H; Seino Y
J Pediatr Endocrinol Metab; 2021 Jun; 34(6):791-798. PubMed ID: 33837680
[TBL] [Abstract][Full Text] [Related]
33. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
Takashi Y; Kawanami D; Fukumoto S
Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
[TBL] [Abstract][Full Text] [Related]
34. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
[TBL] [Abstract][Full Text] [Related]
35. Phosphatonins: From Discovery to Therapeutics.
Kritmetapak K; Kumar R
Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
[TBL] [Abstract][Full Text] [Related]
36. Approach to Hypophosphatemic Rickets.
Ackah SA; Imel EA
J Clin Endocrinol Metab; 2022 Dec; 108(1):209-220. PubMed ID: 35981346
[TBL] [Abstract][Full Text] [Related]
37. Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia.
Martín Ramos S; Gil-Calvo M; Roldán V; Castellano Martínez A; Santos F
Front Pediatr; 2020; 8():48. PubMed ID: 32133333
[TBL] [Abstract][Full Text] [Related]
38. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial.
Insogna KL; Rauch F; Kamenický P; Ito N; Kubota T; Nakamura A; Zhang L; Mealiffe M; San Martin J; Portale AA
J Bone Miner Res; 2019 Dec; 34(12):2183-2191. PubMed ID: 31369697
[TBL] [Abstract][Full Text] [Related]
39. Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives.
Seefried L; Duplan MB; Briot K; Collins MT; Evans R; Florenzano P; Hawkins N; Javaid MK; Lachmann R; Ward LM
Front Endocrinol (Lausanne); 2023; 14():1211426. PubMed ID: 37547321
[TBL] [Abstract][Full Text] [Related]
40. Congenital Conditions of Hypophosphatemia Expressed in Adults.
Marcucci G; Brandi ML
Calcif Tissue Int; 2021 Jan; 108(1):91-103. PubMed ID: 32409880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]